Spatial heterogeneity in glioblastoma: linking single-cell and spatial multi-omics to vaccine immunotherapy
- 1Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden
- 2Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden
Abstract
Glioblastoma (GBM) remains the most lethal primary brain tumor, with survival still limited despite advances in multimodal treatment. The tumor’s profound heterogeneity--across patients, within individual tumors, and over time--has frustrated every class of therapeutic intervention. Recent developments in single-cell and spatial omics technologies have substantially advanced our understanding of this heterogeneity. No longer viewed as a uniform mass, GBM is now recognized as a spatially organized ecosystem of distinct malignant cell states, immune neighborhoods, and metabolic niches that interact across macroscopic distances. Spatial transcriptomics has revealed that malignant cells exist along a continuum of transcriptional programs--from neural progenitor-like to mesenchymal-like--that are not randomly distributed but organized into structured regions with a multi-layered architecture associated with hypoxia. Spatial proteomics and imaging mass cytometry have complemented these findings by mapping protein-level immune landscapes, uncovering cellular neighborhoods associated with survival and identifying spatially defined immunosuppressive niches. This review summarizes current knowledge from single-cell and spatial multi-omic studies of GBM, with an emphasis on the spatial organization of malignant cell states, the architecture of the tumor immune microenvironment, and the implications of these findings for therapeutic development, particularly vaccine immunotherapy. We argue that spatial technologies do not replace existing therapeutic pipelines but address a critical blind spot: the spatial dimension that bulk measurements cannot see.
Related
- Spatiotemporal evolution and spatial heterogeneity of driving factors of gonorrhea incidence in Mainland China before and after the COVID-19 pandemic
- Multimodal spatial-omics reveal the heterogeneity and intercellular network characteristics of papillary craniopharyngiomas.
- Spatial–temporal heterogeneity in tuberculosis incidence and its association with socioeconomic factors in South Sulawesi
- Township-level spatial heterogeneity and associated factors of diagnostic delay among pulmonary tuberculosis patients in Central China
- The blood-brain tumor barrier as a spatial immune checkpoint in glioblastoma: leukocyte entry, perivascular retention, and therapeutic implications
BibTeX
@article{yuan2026spatial,
title = {{Spatial heterogeneity in glioblastoma: linking single-cell and spatial multi-omics to vaccine immunotherapy}},
author = {Juan Yuan and Yong Liu},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1921816},
url = {https://doi.org/10.3389/fimmu.2026.1921816},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Spatial heterogeneity in glioblastoma: linking single-cell and spatial multi-omics to vaccine immunotherapy
AU - Juan Yuan
AU - Yong Liu
PY - 2026
DA - 2026/10/12
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1921816
UR - https://doi.org/10.3389/fimmu.2026.1921816
AB - Glioblastoma (GBM) remains the most lethal primary brain tumor, with survival still limited despite advances in multimodal treatment. The tumor’s profound heterogeneity--across patients, within individual tumors, and over time--has frustrated every class of therapeutic intervention. Recent developments in single-cell and spatial omics technologies have substantially advanced our understanding of this heterogeneity. No longer viewed as a uniform mass, GBM is now recognized as a spatially organized ecosystem of distinct malignant cell states, immune neighborhoods, and metabolic niches that interact across macroscopic distances. Spatial transcriptomics has revealed that malignant cells exist along a continuum of transcriptional programs--from neural progenitor-like to mesenchymal-like--that are not randomly distributed but organized into structured regions with a multi-layered architecture associated with hypoxia. Spatial proteomics and imaging mass cytometry have complemented these findings by mapping protein-level immune landscapes, uncovering cellular neighborhoods associated with survival and identifying spatially defined immunosuppressive niches. This review summarizes current knowledge from single-cell and spatial multi-omic studies of GBM, with an emphasis on the spatial organization of malignant cell states, the architecture of the tumor immune microenvironment, and the implications of these findings for therapeutic development, particularly vaccine immunotherapy. We argue that spatial technologies do not replace existing therapeutic pipelines but address a critical blind spot: the spatial dimension that bulk measurements cannot see.
SN - 1664-3224
ER -